It is estimated that 13% of all invasive ovarian cancer patients carry mutations in *BRCA1* or *BRCA2* ([@bib48]; [@bib40]), and an additional proportion of patients carry mutations in genes that increase risk of hereditary non-polyposis colorectal cancer (HNPCC). Hereditary non-polyposis colorectal cancer is an autosomal dominant syndrome of cancer predisposition of the colorectum, endometrium, stomach or ovaries associated with DNA mismatch repair (MMR) gene mutations. Other less frequent sites include cancers of the renal pelvis, ureter, small bowel, pancreas and brain ([@bib19]). Patients may develop multiple primary cancers, and colorectal cancers are characterised by young age of onset ([@bib42]). Hereditary non-polyposis colorectal cancer is believed to account for 2--4% ([@bib15], [@bib14]) of unselected cases of colorectal cancer, but the fraction of ovarian cancer due to HNPCC is not well established. The lifetime risk of ovarian carcinoma in females carrying HNPCC mutations has been estimated to be up to 12%, with a recent report suggesting cumulative risks of 20% or higher for the *MLH1* and *MSH2* genes; however, risk may vary with the specific gene involved ([@bib4]).

In most studies of HNPCC families to-date, *MLH1* and *MSH2* account for 80--90% of observed mutations in the MMR genes ([@bib27]; [@bib29]). However, most studies were clinic-based surveys of individuals tested based on clinical criteria, such as the Amsterdam criteria ([@bib44]), and few included *MSH6* testing. Mutations in *MSH6* ([@bib22]; [@bib35]) are infrequent in classical HNPCC families, and thus may have been underestimated in prior studies.

Identification of germline MMR genes enables individuals to benefit from up-to-date cancer risk management options as outlined in the NCCN guidelines ([@bib20]). In fact, frequent colonoscopy has been shown to improve outcome ([@bib37]; [@bib43]). Furthermore, endometrial and ovarian cancer risk management options include both screening and prophylactic surgery, once childbearing is complete. In addition, preliminary studies in colorectal cancer suggest that knowledge of germline MMR gene mutations may provide an opportunity to refine cancer treatment ([@bib10], [@bib11]; [@bib16]).

The objective of the current study was to estimate the frequency of mutations in the three HNPCC genes in a population-based sample of women with epithelial ovarian cancer. Secondary objectives included evaluation of demographic, clinical, histopathologic and family history characteristics of germline mutation carriers.

Materials and methods
=====================

Participants
------------

Data for this study were drawn from three population-based studies of epithelial ovarian cancer: the Familial Ovarian Tumour Study (FOTS) in Toronto ([@bib32]), the Tampa Bay Ovarian Cancer Study (TBOCS) at the Moffitt Cancer Center ([@bib24]) and the North Carolina Ovarian Cancer Study (NCOCS) at the Duke University ([@bib47]), with details about study design, populations and data collection methods published previously. Briefly, FOTS cases were identified through monitoring of pathology reports submitted to the population-based Ontario Cancer Registry for province-wide recruitment. The TBOCS cases were recruited through a rapid case ascertainment mechanism in the two most populous counties in the Tampa Bay region. The NCOCS cases were identified through a rapid case ascertainment mechanism in a 48-county region located in the central portion of North Carolina ([@bib47]). The study protocol was approved by the institutional review board at each centre, and written informed consent was obtained from all participants. There was no mechanism of rapid ascertainment in place to recruit the FOTS cases, in contrast to the TBOCS and NCOCS cases, which resulted in a longer time from diagnosis to ascertainment in the Toronto centre compared with the American centres.

Eligibility criteria for study enrolment included diagnosis of incident, pathologically confirmed primary epithelial ovarian cancer, either borderline or invasive, and age 20 years or above. Each study collected questionnaire data concerning demographic, clinical and family history information, and reviewed medical and pathology records for determining tumour histopathology. Specimen collection included blood for DNA extraction and analysis.

Gene sequencing
---------------

All 45 coding exons of the *MLH1* (NM_000249.3), *MSH2* (NM_000251.1) and *MSH6* (NM_000179.2) genes were amplified and sequenced in 44 fragments in germline DNA. Primers were designed using Primer 3 software ([@bib33]) to cover at least 20 bp at each 5′- and 3′-side of the exons. The amplified DNA fragments were sequenced by using the BigDye Terminator Cycle Sequencing kit on an ABI 3730xl DNA Analyzer (Applied Biosystems Co., Foster City, CA, USA). Sequencing chromatograms generated by the analyser were examined for variant detection using Mutation Surveyor software (SoftGenetics LLC., State College, PA, USA). All sequences were compared with the related NCBI (<http://www.ncbi.nlm.nih.gov>) reference sequences for variant detection. The chromatograms of all the computationally determined variants were confirmed manually.

All insertions and deletions in the gene-coding regions, nonsense variants and variants located at the essential splice site sequences were considered as potentially pathogenic, and their DNA fragments were also sequenced in the reverse direction for confirmation. Insertions and deletions for which no functionality data were available were classified as 'unknown pathogenicity\'. Missense variants first were searched in the colon cancer gene variant database (<http://chromium.liacs.nl/LOVD2/colon_cancer/home.php>) for functional effects. If functional effect was not known, we used Align-GVGD ([@bib38]) to predict the likely functional effect based on library alignments from human to pufferfish for *MLH1* and *MSH2*. As no alignment data were available for *MSH6* in the Align-GVGD website, a protein alignment was constructed for predicting the functional effect of *MSH6* missense variants from *MSH6* homologues in eight species (human, chimpanzee, dog, cow, pig, mouse, chicken, frog and zebrafish). Missense variants with class C45 and higher defined by Align-GVGD were classified as 'predicted pathogenic\'. The class C45 was chosen as a cut-off point for Align-GVGD based on receiver-operating characteristic curve analysis using *BRCA1* and *BRCA2* missense variants with known functional effects reported in the Breast Cancer Information Core database (<http://research.nhgri.nih.gov/projects/bic/>) or Myriad\'s published data ([@bib9]). The rationale for using *BRCA1* and *BRCA2* mutations for the receiver-operating characteristic curve analysis was the limited sample size of known pathogenic missense mutations in the *MLH1*, *MSH2* and *MSH6* genes. The chosen cut-off point corresponds to 90% specificity and 50% sensitivity. We also used PolyPhen2 ([@bib1]) and SIFT ([@bib23]) for predicting the functional effect of missense variants. We considered a missense variant as a predicted pathogenic if two of the three *in silico* tools (Align-GVGD, PolyPhen-2 and SIFT) predicted it as pathogenic and the carrier frequency of that mutation was less than 1% among 6481 study subjects of the NHLBI Exome Sequencing Project (ESP6500) (<http://evs.gs.washington.edu/EVS/>).

Data collection
---------------

All participants completed questionnaires by which demographic and family history information was obtained. Family history data included types and ages of cancer diagnoses in first-, second- and third-degree relatives. In addition, the FOTS data set included ages of relatives (current, or if deceased, age at death). Medical records were retrieved on all participants to abstract information on tumour histology. Information on date of diagnosis (based on pathology report) and date of study enrolment (based on date consent form was signed) were collected, to determine time between diagnosis and enrolment (calculated in days).

Statistical analyses
--------------------

Site differences in descriptive statistics of clinical factors across the three sites were evaluated using analysis of variance and Kruskal--Wallis tests for continuous variables (e.g., time to diagnosis and attained age) and Pearson\'s *χ*^2^-tests for categorical variables. Similarly, clinical variables were compared across mutation subtypes (i.e., pathogenic, predicted pathogenic, predicted non-pathogenic, no mutation detected). Known benign polymorphic variants were combined with the 'no mutation\' group. All reported *P*-values are two-sided. All analyses were carried out with SAS version 9.1.3 (SAS Institute, Inc., Cary, NC, USA).

To compare the cumulative incidence of cancer among the first-degree relatives of proband carriers of different mutation subtypes, a survival analysis approach among the FOTS study subjects for whom we had detailed family history information was used. Each first-degree relative was considered as an observation and followed from birth until the occurrence of any type of cancer, death from another cause, or the date of the study interview, using the Cox proportional hazard model. Separate analyses were carried out for all cancer outcomes, all HNPCC cancer outcomes, colorectal cancer outcome and ovarian cancer outcome. Covariates for each observation included the proband\'s mutation status. Hazard ratios of mutation subtypes and 95% confidence interval (CI) were estimated for each model.

Results
=======

In total, 1893 ovarian cancer patients were included, with 1521 from FOTS, 126 from TBOCS and 246 from NCOCS, as shown in [Table 1](#tbl1){ref-type="table"}. Overall, mean age at diagnosis and racial distribution were similar between sites, other than a higher proportion of Black subjects in the Duke sample. The median time between diagnosis and study enrolment was similar between the Duke and Moffitt cases, although longer for the Toronto cases because of the difference in participant ascertainment procedure. At all three sites, the majority of cancers were of serous histology. However, the proportion of non-serous cases was higher in the Ontario case than in the other two sites. Family histories of HNPCC-associated cancers were similar across the three sites.

Germline genetic testing of coding regions in the *MLH1*, *MSH2* and *MSH6* genes revealed sequence changes at 161 different nucleotides. As shown in [Table 2](#tbl2){ref-type="table"}, nine pathogenic mutations were found, five in *MSH6*, two in *MLH1* and two in *MSH2*. Four mutations were insertions or deletions and five were nonsense mutations. Seven of the nine pathologic mutations have been previously reported and each of the nine was seen in a single individual. We detected two additional changes of 'unknown pathogenicity\' in *MSH6*: an in-frame deletion of two amino acids (*MSH6* c.936_941delGAAAAG), not known to belong to any known functional protein domain, and a frame-shift insertion (*MSH6* c.4065_4066insGTGA) at the C terminus that truncates two terminal amino acids. In addition, there were 101 missense variants ([Supplementary Table 1](#sup1){ref-type="supplementary-material"}), including 5 benign polymorphisms, and 96 unclassified variants (in 128 participants) and 49 silent variants ([Supplementary Table 2](#sup1){ref-type="supplementary-material"}). Overall, the frequency of pathogenic mutations was 0.5% (95% CI 0.2--0.8; [Table 2](#tbl2){ref-type="table"}). However, this frequency was 1.6% (95% CI 0.4--2.7) when considering only invasive cancers of the endometrioid and clear cell subtypes.

Through the Align-GVGD, PolyPhen and SIFT algorithms, pathogenicity was evaluated in the 96 unclassified variants, by which 28 unclassified variants (in 55 participants) were classified as 'predicted pathogenic\' and 68 (in 99 participants) as 'predicted non-pathogenic\'. To further evaluate our predictions of pathogenicity, we compared the penetrance among 9015 first-degree relatives of 1521 FOTS participants by mutation subtype. Results showed that cumulative risk to age 80 years of any cancer in those with pathogenic mutations was 56.7% compared with 44.2, 21.0 and 27.4% for those in the 'predicted pathogenic\', predicted 'non-pathogenic\', and no mutations groups, respectively. A similar result was seen for the risk of developing HNPCC-related cancer, but the difference between the groups did not reach customary statistical significance ([Table 3](#tbl3){ref-type="table"}). Cumulative risk of ovarian cancer among relatives of mutation carriers compared with relatives of non-carriers was not elevated, likely due to the limited number of relatives with ovarian cancer.

The average age of onset of ovarian cancer was 47.1 years in the 'pathogenic group\' ([Table 4](#tbl4){ref-type="table"}) and 53.2 years in the 'predicted pathogenic group\', compared with 56.1 years in those with no mutations. Non-serous cancers comprised 77.8% in the 'pathogenic group\' and 66% in the 'predicted pathogenic group\', compared with 41.9% in those with no mutations. The number of relatives with HNPCC-related cancers was highest in the 'pathogenic\' group; however, findings in the other three groups indicated similar proportions. Of note, the proportion of mutations in the four mutation subgroups was similar across study sites (*P*=0.2). Specifically, the proportion of mutation carriers in the Moffitt, Duke and Toronto samples was 0.8%, 0.4% and 0.5%, respectively, despite the longer time from diagnosis to enrolment in the Toronto cases.

Finally, review of family histories of those with pathogenic and predicted pathogenic mutations indicated the two families that met clinical criteria for HNPCC ([@bib44]) carried pathogenic *MLH1* mutations. Furthermore, the two families with pathogenic *MSH2* mutations had striking family histories, despite not meeting clinical criteria. All remaining families did not meet clinical criteria.

Discussion
==========

We determined the frequency of germline mutations in three MMR genes in a population-based sample of 1893 women with ovarian cancer. Our findings suggest that pathogenic germline MMR mutations are found in less than 1% of unselected ovarian cancer cases, with a higher frequency in those with invasive cancers of the endometrioid and clear cell subtypes. Of the nine pathogenic mutations clearly identified, the majority (55%) were detected in the *MSH6* gene.

The pathogenic mutations clearly identified in our study were classified based on protein truncation or on previous epidemiologic or functional studies. Our findings likely represent an underestimate of the true proportion, as there were several missense variants for which pathogenicity could not be definitively determined. Furthermore, we did not test for additional less common MMR genes (*PMS2*, *EPCAM*) or for large gene rearrangements, which may have detected additional pathogenic mutations ([@bib7]; [@bib12]; [@bib41]; [@bib13]; [@bib18]).

For the many missense variants detected in the study, databases such as UniProt ([www.uniprot.org](http://www.uniprot.org)) and Human Genome Mutation Database ([www.hgmd.org](http://www.hgmd.org)) were explored to determine pathogenicity. Of note, UniProt, a protein database, had many errors in functional classification of missense variants and, thus, is unreliable for definitively determining the functional effect of individual variants. Similarly, the Human Genome Mutation Database, a manually curated database, classifies many missense mutations as disease-causing without providing compelling evidence from the literature to support the assignments. Consequently, we focused on bioinformatic tools to establish the pathogenicity of missense variants ([@bib39]). Specifically, we used the Align-GVGD ([@bib38]) algorithm by means of a manually curated protein alignment across species of broad phylogenic scope in combination with a stringent cut-off point to predict the dysfunctional effect of a variant. This method outperforms other bioinformatic tools ([@bib2]) such as SIFT ([@bib23]) and PolyPhen2 ([@bib1]). However, we used the combination of these three tools for predicting the functional effect of the missense variants. We also looked at the carrier frequency of these variants in ESP6500 database and considered the frequently reported ones as predicted 'non-pathogenic\'. We detected 28 missense mutations (in 55 participants) classified as 'predicted pathogenic\' using these tools. Thus, if all of these are in fact pathogenic, the prevalence of MMR gene mutation carriers among ovarian cancer patients would be 3.6% or higher. Of note, we chose not use the MAPP-MMR tool ([@bib5]; which is another bioinformatics tool with no clear advantage to other tools), because it only predicts the functional effects in *MLH1* and *MSH2* genes, whereas over 40% of the missense variants identified in our sample were in *MSH6*. Furthermore, because of conflicting reports in the literature regarding pathogenicity of certain variants (e.g., *MLH1* p.Lys618A1a, observed in 24 participants in our study, was previously reported as both non-pathogenic ([@bib30]) and pathogenic; [@bib28]), we reported predictions of pathogenicity according to aforementioned criteria rather than based on prior published reports, which are in essence based on predictions.

Prior estimates of the frequency of germline MMR mutations in ovarian cancer patients have been less than 5% ([@bib34]; [@bib36]), based on studies of 116 patients or fewer and limited to the *MLH1* and *MSH2* genes only. Moreover, one of the studies was restricted to women aged 30 years or less at diagnosis ([@bib36]). Thus, although our prevalence estimates are generally lower than prior reports, the validity and generalisability of our data is enhanced by the much larger sample size, performance of testing in all three genes (i.e., including *MSH6*) and inclusion criteria that encompassed a wider age group of participants.

Although most studies have focused on *MLH1* and *MSH2*, several have reported ovarian cancer in the *MSH6* tumour spectrum ([@bib22]; [@bib50]; [@bib45]; [@bib4]). However, in contrast to prior reports suggesting only 10% of HNPCC families harbour *MSH6* mutations ([@bib49]; [@bib3]), such mutations accounted for over half of the clearly pathogenic mutations in our study. The low percentage of *MSH6* mutations may be due to inadequate clinical criteria to accurately identify these families ([@bib35]), who typically present with later age of colorectal cancer, and higher risk but later age of endometrial cancer in females ([@bib49]; [@bib45]; [@bib8]; [@bib31]). Thus, although infrequent in classical HNPCC families, our results suggest *MSH6* mutations may be better represented in families with ovarian cancer. In fact, a recent study of 67 *MLH1*, *MSH2* and *MSH6* mutation carriers ascertained through a family cancer clinic included 10 ovarian cancers, of which the majority were seen in *MSH6* carriers ([@bib31]), consistent with our study findings. Interestingly, none of the families with pathogenic *MSH6* mutations in our study met clinical criteria for HNPCC ([@bib44]). In contrast, both *MLH1* families met clinical criteria, and both *MSH2* families had striking family histories, despite not meeting clinical criteria. Of note, clinical criteria do not include cancers of the ovary and stomach, yet these cancers are much more common in HNPCC compared with those of the small bowel, ureter and renal pelvis, which are included. Ultimately, our study underscores the limitations of the use of HNPCC clinical diagnostic criteria based only on personal and family cancer history to identify *MSH6* families.

Our results were consistent with prior reports, suggesting an earlier age at diagnosis of ovarian cancer in carriers (mean ranging from 41 to 49 years) compared with sporadic cases (mean ranging from 60 to 65 years) ([@bib46]; [@bib6]; [@bib21]). Moreover, our age of diagnosis ranged from 40 to 59 years, which suggests that prophylactic surgery offered before age 40 years is likely to prevent the majority of HNPCC-associated ovarian cancers. Furthermore, the overrepresentation of non-serous tumours, particularly of endometrioid and clear cell subtypes ([@bib25], [@bib26]; [@bib17]), reported in HNPCC is consistent with our findings. Finally, as in our prior studies ([@bib2]), we used a cohort analysis to evaluate the Align-GVGD predictions. For example, if the predicted pathogenic mutations have the same penetrance, on average as the clearly pathogenic mutations, then we would expect to see cancer risks in first-degree relatives of patients in the two subgroups to be similar. In our study, although the penetrance of predicted pathogenic variants was slightly lower than the pathogenic variants, it was still consistently higher than the 'predicted non-pathogenic\' and 'no mutation\' groups, thus suggesting that many in this class are likely pathogenic. A deviation from this trend was seen in the lifetime risk of ovarian cancer illustrated in [Table 3](#tbl3){ref-type="table"}, which was lowest in the 'pathogenic mutation\' group; however, this may be a spurious finding due to the limited number of relatives with ovarian cancer. Overall, the combined frequency of pathogenic and predicted pathogenic mutations was 3.6% (95% CI 2.9--4.6; [Table 2](#tbl2){ref-type="table"}). However, this frequency was 6.3% (95% CI 4.3--9.2) when considering only invasive cancers of the endometrioid and clear cell subtypes.

A number of strengths support the current study, including the large sample size, the population-based study design and comprehensive collection of clinical and demographic data. Despite these strengths, there remain some limitations, including our testing strategy that may have led to underestimating mutation frequency. Specifically, because of limited resources, large rearrangement testing was not performed, which may account for 10--20% of mutations in the MMR genes ([@bib12]; [@bib41]; [@bib13]). Similarly, testing for the two additional MMR genes, which has recently become available (i.e., *PMS2* ([@bib7]) and *EPCAM* ([@bib18])) was also not performed in the current study. In addition, differences in demographic and clinical variables across sites (as reported in [Table 1](#tbl1){ref-type="table"}) could potentially affect our results. Notably, the time to diagnosis in FOTS cases was significantly longer than that for TBOCS or NCOCS, leading to overrepresentation of cases with longer survival in the FOTS data set. However, the main concern here is whether a longer time to diagnosis led to overrepresentation of mutation-positive cases in the FOTS data set, thereby biasing our mutation prevalence estimate. If this were true, the proportion of mutation-positive cases in the FOTS sample would be higher, which was not the case (as illustrated in [Table 4](#tbl4){ref-type="table"}). Therefore, it appears the longer time to diagnosis in the FOTS data set did not appear to substantially affect the mutation prevalence estimate. Nevertheless, the presence of survival bias within the FOTS data may have skewed the clinical characteristics within the overall data set as suggested by the higher proportions of non-serous cases observed. However, there remained an association between non-serous histologies and HNPCC mutations, which was likely underestimated because of the lower numbers of serous cases within the data set. Finally, we were limited in our ability to predict pathogenicity in many of the missense mutations because of sparse data available in the literature and mutation databases. To address this, we used an *in silico* approach to predict the dysfunctional effect of the detected missense variants, recognising that inherent inaccuracy of bioinformatics tools could result in some misclassification of the variants. However, our findings suggest that many are likely to be pathogenic based on similarities in the clinical and demographic characteristics with the pathogenic group (as shown in [Tables 3](#tbl3){ref-type="table"} and [4](#tbl4){ref-type="table"}).

In summary, we estimate that less than 1% of unselected ovarian cancer patients may have mutations in the MMR genes, with overrepresentation of *MSH6* mutations in those with invasive cancers of the endometrioid and clear cell subtypes. Ovarian tumours with MMR-deficiency are characterised by early age of onset and overrepresentation of non-serous cancers. Our results suggest that current clinical criteria for HNPCC are insufficient to identify the majority of ovarian cancer patients with mutations. These findings highlight the need to consider HNPCC testing in women with ovarian cancer, particularly those with invasive cancers of the endometrioid and clear cell subtypes, even if they do not meet strict clinical criteria for the condition.
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###### 
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###### Demographic and clinical characteristics of ovarian cancer patients by study site

                                                                                   **Overall (*****N*****=1893)**   **Duke (*****N*****=246)**   **Moffitt (*****N*****=126)**   **Toronto (*****N*****=1521)**   ***P*****-value**
  -------------------------------------------------------------------------------- -------------------------------- ---------------------------- ------------------------------- -------------------------------- -------------------
  Mean age (s.d.)                                                                  56.0 (12.2)                      55.2 (11.3)                  56.7 (11.6)                     56.1 (12.4)                      0.45
                                                                                                                                                                                                                   
  *Race*, n *(%)*                                                                                                                                                                                                 
   Caucasian                                                                       1751 (92.5)                      213 (86.6)                   121 (96.0)                      1417 (93.2)                      \<0.0001
   Black                                                                           38 (2.0)                         28 (11.4)                    2 (1.6)                         8 (0.5)                           
   Asian                                                                           94 (5.0)                         2 (0.8)                      3 (2.4)                         89 (5.9)                          
   Other                                                                           10 (0.5)                         3 (1.2)                      0 (0)                           7 (0.5)                           
                                                                                                                                                                                                                   
  Time from diagnosis to interview, days (median)                                  613                              118                          108                             677                              \<0.0001
                                                                                                                                                                                                                   
  *Histology*                                                                                                                                                                                                     
   Borderline, *n* (%)                                                             255 (13.5)                       51 (20.7)                    15 (11.9)                       189 (12.4)                       0.0019
   Invasive, *n* (%)                                                               1638 (86.5)                      195 (79.3)                   111 (88.1)                      1332 (87.6)                       
    Serous, *n* (%)                                                                933 (57.0)                       130 (66.7)                   66 (59.5)                       737 (55.3)                       0.0099
    Non-serous, *n* (%)                                                            705 (43.0)                       65 (33.3)                    45 (40.5)                       595 (44.7)                        
     Clear cell                                                                    116 (7.1)                        15 (7.7)                     8 (7.2)                         93 (7.0)                         0.17
     Endometrioid                                                                  313 (19.1)                       20 (10.3)                    19 (17.1)                       274 (20.6)                        
     Mucinous                                                                      127 (7.8)                        9 (4.6)                      5 (4.5)                         113 (8.5)                         
     Other[a](#t1-fn2){ref-type="fn"}                                              149 (9.1)                        21 (10.8)                    13 (11.7)                       115 (8.6)                         
                                                                                                                                                                                                                   
  *Family history*, n *(%)*[b](#t1-fn3){ref-type="fn"}                                                                                                                                                            
   % of subjects with relatives with colorectal cancer                             363 (19.2)                       34 (13.8)                    20 (15.9)                       309 (20.3)                       0.037
   % of subjects with relatives with endometrial cancer                            59 (3.1)                         11 (4.5)                     8 (6.3)                         40 (2.6)                         0.031
   % of subjects with relatives with any HNPCC cancer[c](#t1-fn4){ref-type="fn"}   637 (33.7)                       80 (32.5)                    38 (30.2)                       519 (34.1)                       0.61

Abbreviation: HNPCC=hereditary non-polyposis colorectal cancer.

Other includes the following histologies: carcinoma, unspecified (108), mixed cell (34), ovarian surface epithelial tumour (1), primary peritoneal (1) and transitional cell carcinoma (5).

Family history used the following relatives: mother, father, sisters, brothers, daughters, sons, grandmother, grandfather, aunt, uncle, nieces, nephews, halfsiblings.

The HNPCC cancer sites included colorectum, endometrium, other gastrointestinal tract, urinary tract, ovary and brain.

###### Summary of pathogenic, predicted pathogenic and unknown variants in the MMR genes

       **Gene**   **Mutation**            **Protein change**    **Mutation type**   **Functional effect**   **GVGD prediction**   **PolyPhen prediction**   **SIFT prediction**  **ESP6500 carrier frequency**   **No. of individuals with mutation**
  ---- ---------- ----------------------- -------------------- ------------------- ----------------------- --------------------- ------------------------- --------------------- ------------------------------- --------------------------------------
   1   *MLH1*     c.676C\>T               p.Arg226X                     N                     P                     NA                      NA                      NA           0                               1
   2   *MLH1*     c.1852_1854delAAG       p.Lys618del                  ID                     P                     NA                      NA                      NA           0                               1
   3   *MSH2*     c.163delC               p.Arg55GlyfsX9               FD                     P                     NA                      NA                      NA           0                               1
   4   *MSH2*     c.2038C\>T              p.Arg680X                     N                     P                     NA                      NA                      NA           0                               1
   5   *MSH6*     c.1636 G\>T             P.Arg312_Lys313del            N                     P                     NA                      NA                      NA           0                               1
   6   *MSH6*     c.2150_2153delTCAG      p.Glu546X                    FD                     P                     NA                      NA                      NA           0                               1
   7   *MSH6*     c.2690_2691insA         p.Val717fsX18                FI                     P                     NA                      NA                      NA           0                               1
   8   *MSH6*     c.2731C\>T              p.Asn897fsX3                  N                     P                     NA                      NA                      NA           1                               1
   9   *MSH6*     c.3103C\>T              p.Arg911X                     N                     P                     NA                      NA                      NA           0                               1
  10   *MSH6*     c.936_941delGAAAAG      p.Arg1035X                   ID                     U                     NA                      NA                      NA           0                               1
  11   *MSH6*     c.4065_4066insGTGA      p.Leu1356fsX4                FI                     U                     NA                      NA                      NA           0                               1
  12   *MLH1*     c.47T\>G                p.Val16Gly                    M                    PP                  Class C65                  PrD                      D           0                               1
  13   *MLH1*     c.1136A\>G              p.Tyr379Cys                   M                    PP                  Class C25                  PoD                      D           2                               1
  14   *MLH1*     c.1148T\>C              p.Met383Thr                   M                    PP                  Class C65                  PrD                      D           2                               1
  15   *MLH1*     c.1151T\>A              p.Val384Asp                   M                    PP                  Class C65                  PrD                      D           1                               3
  16   *MLH1*     c.1489C\>G              p.Arg497Gly                   M                    PP                  Class C45                  PoD                      T           0                               1
  17   *MLH1*     c.1808C\>G              p.Pro603Arg                   M                    PP                  Class C65                  PoD                      D           1                               1
  18   *MLH1*     c.1852_1853delAAinsGC   p.Lys618Ala                   M                    PP                  Class C65                  PrD                      D           0                               24
  19   *MLH1*     c.1870G\>C              p.Asp624His                   M                    PP                  Class C0                   PrD                      D           0                               1
  20   *MLH1*     c.1937A\>G              p.Tyr646Cys                   M                    PP                  Class C65                  PrD                      D           0                               1
  21   *MSH2*     c.1A\>C                 p.Met1Leu                     M                    PP                  Class C0                   PrD                      D           0                               1
  22   *MSH2*     c.138C\>G               p.His46Gln                    M                    PP                  Class C15                  PrD                      D           3                               1
  23   *MSH2*     c.166G\>A               p.Glu56Lys                    M                    PP                  Class C55                  PrD                      T           0                               1
  24   *MSH2*     c.1044G\>C              p.Gln348His                   M                    PP                  Class C15                  PrD                      D           0                               1
  25   *MSH2*     c.1432C\>T              p.Leu478Phe                   M                    PP                  Class C15                  PrD                      D           0                               1
  26   *MSH2*     c.1927G\>A              p.Glu643Lys                   M                    PP                  Class C55                  PrD                      D           1                               1
  27   *MSH2*     c.2203A\>G              p.Ile735Val                   M                    PP                  Class C25                  PoD                      D           3                               1
  28   *MSH2*     c.2542G\>T              p.Ala848Ser                   M                    PP                  Class C65                  PoD                      D           0                               1
  29   *MSH2*     c.2558A\>G              p.Glu853Gly                   M                    PP                  Class C65                  PoD                      D           0                               1
  30   *MSH2*     c.2732T\>G              p.Leu911Arg                   M                    PP                  Class C45                  PrD                      D           0                               1
  31   *MSH6*     c.437G\>C               p.Arg146Thr                   M                    PP                  Class C25                  PrD                      D           0                               1
  32   *MSH6*     c.802G\>C               p.Asp268His                   M                    PP                  Class C0                   PrD                      D           0                               1
  33   *MSH6*     c.2561A\>T              p.Lys854Met                   M                    PP                  Class C65                  PrD                      D           5                               1
  34   *MSH6*     c.2594T\>G              p.Phe865Cys                   M                    PP                  Class C65                  PoD                      T           0                               1
  35   *MSH6*     c.2752C\>T              p.His918Tyr                   M                    PP                  Class C65                  PrD                      T           0                               1
  36   *MSH6*     c.3259C\>T              p.Pro1087Ser                  M                    PP                  Class C65                  PoD                      T           4                               1
  37   *MSH6*     c.3407A\>G              p.Asn1136Ser                  M                    PP                  Class C45                  PrD                      D           0                               2
  38   *MSH6*     c.3722G\>A              p.Cys1241Tyr                  M                    PP                  Class C65                  PrD                      D           0                               1
  39   *MSH6*     c.3938T\>C              p.Ile1313Thr                  M                    PP                  Class C65                  PoD                      T           0                               2

Abbreviations: D=damaging; FD=frameshift deletion; FI=frameshift insertion; GVGD=Grantham Variation and Grantham Deviation; ID=in-frame deletion; M=missense; MMR=mismatch repair; N=nonsense; P=pathogenic; PoD=possibly damaging; PP=predicted pathogenic; PrD=probably damaging; T=tolerated; U=unknown.

###### Penetrance of cancer among 9015 first degree relatives of 1521 FOTS participants by mutation subtype

  **Cohort groups of first-degree relatives**           **Affected relatives/total relatives**  **Cumulative risk to age 80, % (s.e.)**    **Hazard ratio**   **95% Confidence interval**  ***P*****-value**
  ---------------------------------------------------- ---------------------------------------- ----------------------------------------- ------------------ ----------------------------- -------------------
  *All cancers*                                                                                                                                                                            
   No mutation                                                         876/7905                 27.4 (0.9)                                    Reference                                     
   Pathogenic mutation                                                   8/33                   56.7 (15.2)                                      4.72                 2.33--9.56           \<0.0001
   Unclassified variant                                                 73/640                  28.7 (3.4)                                       1.09                 0.86--1.38           0.5
   Predicted pathogenic                                                 35/205                  44.2 (6.7)                                       1.75                 1.24--2.45           0.001
   Predicted non-pathogenic                                             38/435                  21.0 (3.4)                                       0.81                 0.58--1.12           0.20
                                                                                                                                                                                            
  *HNPCC-related cancers*[a](#t3-fn3){ref-type="fn"}                                                                                                                                       
   No mutation                                                         345/7890                 13.0 (2.7)                                    Reference                                     
   Pathogenic mutation                                                   4/33                   28.8 (13.5)                                      6.12                 2.26--16.5           0.0004
   Unclassified variant                                                 25/626                  11.9 (2.6)                                       0.93                 0.62--1.40           0.73
   Predicted pathogenic                                                 11/202                  17.1 (5.7)                                       1.33                  0.73--243           0.35
   Predicted non-pathogenic                                             14/424                  9.0 (2.8)                                        0.76                 0.44--1.29           0.31
                                                                                                                                                                                            
  *Colorectal cancer*                                                                                                                                                                      
   No mutation                                                         120/8023                 5.3 (0.5)                                     Reference                                     
   Pathogenic mutation                                                   3/33                   16.9 (9.2)                                       15.5                 4.88--49.5           \<0.0001
   Unclassified variant                                                 9/653                   5.5 (2.1)                                        0.96                 0.49--1.89           0.9
   Predicted pathogenic                                                 3/2114                  8.2 (0.5)                                        1.05                 0.33--3.29           0.94
   Predicted non-pathogenic                                             6/442                   4.3 (2.2)                                        0.92                 0.41--2.09           0.84
                                                                                                                                                                                            
  *Ovarian cancer*[b](#t3-fn4){ref-type="fn"}                                                                                                                                              
   No mutation                                                         67/4166                  3.6 (0.5)                                     Reference                                     
   Pathogenic mutation                                                   0/16                   0 (0.0)                                           0                 Not applicable         0.99
   Unclassified variant                                                 6/325                   3.4 (1.5)                                        1.16                 0.50--2.67           0.73
   Predicted pathogenic                                                 3/104                   4.3 (2.5)                                        2.00                 0.63--6.37           0.24
   Predicted non-pathogenic                                             3/221                   3.1 (1.8)                                        0.81                 0.26--2.59           0.72

Abbreviations: FOTS=Familial Ovarian Tumour Study; HNPCC=hereditary non-polyposis colorectal cancer.

Note the following categories of genetic test results: unclassified variants, missense variants with uncertain functional effect; predicted pathogenic, predicted based on Align-Grantham Variation and Grantham Deviation.

The HNPCC cancer sites included colorectum, endometrium, other gastrointestinal tract, urinary tract, ovary and brain.

Female first-degree relatives of the probands were included in this analysis.

###### Mutation subtype by demographic, clinical, histopathologic and family history variables

                                                                         **Pathogenic (*****n*****=9)**   **Predicted pathogenic (*****n*****=61)**   **Predicted non-pathogenic (*****n*****=91)**   **No mutation detected (*****n*****=1730)**   ***P*****-value**
  ---------------------------------------------------------------------- -------------------------------- ------------------------------------------- ----------------------------------------------- --------------------------------------------- -------------------
  *Mean age (s.d.)*                                                      47.1 (6.0)                       53.2 (15.2)                                 57.1 (11.9)                                     56.1 (12.1)                                   0.032
   Age ⩽50, *n* (%)                                                      7 (77.8)                         26 (42.6)                                   31 (34.1)                                       563 (32.5)                                    0.012
   Age \>50, *n* (%)                                                     2 (22.2)                         35 (57.4)                                   60 (65.9)                                       1167 (67.5)                                    
                                                                                                                                                                                                                                                     
  *Race*, n *(%)*                                                                                                                                                                                                                                   
   Caucasian                                                             8 (88.9)                         56 (93.4)                                   75 (82.4)                                       1610 (93.1)                                    
   Black                                                                 1 (11.1)                         1 (1.6)                                     3 (3.3)                                         32 (1.8)                                      0.056
   Asian                                                                 0 (0)                            3 (5.0)                                     13 (14.3)                                       78 (4.5)                                       
   Other                                                                 0 (0)                            0 (0)                                       0 (0)                                           10 (0.6)                                       
                                                                                                                                                                                                                                                     
  Time from diagnosis to interview, days (median)                        784                              576                                         671                                             610.5                                         0.271
                                                                                                                                                                                                                                                     
  *Histology*                                                                                                                                                                                                                                       
   Borderline, *n* (%)                                                   0 (0)                            11 (18.0)                                   6 (6.6)                                         237 (13.7)                                    0.083
   Invasive, *n* (%)                                                     9 (100)                          50 (82.0)                                   85 (93.4)                                       1493 (86.3)                                    
    Serous, *n* (%)                                                      2 (22.2)                         17 (34.0)                                   45 (52.9)                                       868 (58.1)                                    0.001
    Non-serous, *n* (%)                                                  7 (77.8)                         33 (66.0)                                   40 (57.1)                                       625 (41.9)                                     
     Clear cell                                                          2 (28.6)                         6 (18.2)                                    8 (20.0)                                        100 (16)                                       
     Endometrioid                                                        5 (71.4)                         16 (48.5)                                   20 (50.0)                                       272 (43.5)                                    0.801
     Mucinous                                                            0 (0)                            5 (15.2)                                    5 (12.5)                                        117 (18.7)                                     
     Other[a](#t4-fn2){ref-type="fn"}                                    0 (0)                            6 (18.2)                                    7 (17.5)                                        136 (21.8)                                     
                                                                                                                                                                                                                                                     
  *Family history*[b](#t4-fn3){ref-type="fn"}                                                                                                                                                                                                       
   Relatives with colorectal cancer, *n* (%)                             4 (44.4)                         8 (13.3)                                    16 (17.4)                                       335 (19.4)                                    0.143
   Relatives with endometrial cancer, *n* (%)                            0 (0)                            1 (1.7)                                     4 (4.3)                                         54 (3.1)                                      0.731
   Relatives with any HNPCC cancer[c](#t4-fn4){ref-type="fn"}, *n* (%)   4 (44.4)                         18 (30)                                     31 (33.7)                                       584 (33.8)                                    0.832
                                                                                                                                                                                                                                                     
  *Number of mutations*                                                                                                                                                                                                                             
   Toronto, *n* (proportion)                                             7 (0.5)                          41 (2.7)                                    76 (5.0)                                        1396 (91.8)                                    
   Tampa, *n* (proportion)                                               1 (0.8)                          6 (4.8)                                     5 (4.0)                                         114 (90.5)                                    0.244
   Duke, *n* (proportion)                                                1 (0.4)                          14 (5.7)                                    10 (4.1)                                        220 (89.8)                                     

Abbreviations: HNPCC=hereditary non-polyposis colorectal cancer.

Other includes the following histologies: carcinoma, unspecified (108), mixed cell (34), ovarian surface epithelial tumour (1), primary peritoneal (1) and transitional cell carcinoma (5).

Family history used the following relatives: mother, father, sisters, brothers, daughters, sons, grandmother, grandfather, aunt, uncle, nieces, nephews, halfsiblings.

The HNPCC cancer sites included colorectum, endometrium, other gastrointestinal tract, urinary tract, ovary and brain.

[^1]: Joint first authors.
